DOI:
10.1055/s-00000007
Aktuelle Urologie
LinksClose Window
References
Balar AV, Castellano DE, O´Donnell PH. et al.
Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population.
J Clin Oncol 2017; (suppl 6S; abstract 284)
35
DOI: 10.1200IJCO.20/7.35.6_suppl.284.
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.